Trovagene Inc. (TROV) Receives Average Rating of “Hold” from Analysts
Shares of Trovagene Inc. (NASDAQ:TROV) have been given a consensus rating of “Hold” by the nine research firms that are covering the stock. Five analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $6.25.
A number of analysts recently weighed in on the company. Cantor Fitzgerald upgraded Trovagene from a “hold” rating to a “buy” rating and lifted their price target for the company from $5.00 to $7.00 in a research note on Monday, August 8th. Maxim Group lifted their price target on Trovagene from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, August 5th. Zacks Investment Research downgraded Trovagene from a “buy” rating to a “hold” rating in a research note on Tuesday, September 20th. Finally, Piper Jaffray Cos. set a $4.00 price target on Trovagene and gave the company a “hold” rating in a research note on Friday, August 5th.
Several hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Trovagene by 1.3% in the first quarter. Geode Capital Management LLC now owns 183,442 shares of the company’s stock valued at $853,000 after buying an additional 2,363 shares in the last quarter. BlackRock Investment Management LLC increased its stake in shares of Trovagene by 5.6% in the second quarter. BlackRock Investment Management LLC now owns 113,232 shares of the company’s stock valued at $513,000 after buying an additional 5,964 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Trovagene by 39.3% in the second quarter. Rhumbline Advisers now owns 39,171 shares of the company’s stock valued at $177,000 after buying an additional 11,044 shares in the last quarter. First Heartland Consultants Inc. bought a new stake in shares of Trovagene during the second quarter valued at about $103,000. Finally, Vanguard Group Inc. increased its stake in shares of Trovagene by 3.2% in the second quarter. Vanguard Group Inc. now owns 979,014 shares of the company’s stock valued at $4,435,000 after buying an additional 30,369 shares in the last quarter. Institutional investors and hedge funds own 31.05% of the company’s stock.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/trovagene-inc-trov-receives-average-rating-of-hold-from-analysts.html
Shares of Trovagene (NASDAQ:TROV) traded up 1.6683% during mid-day trading on Monday, hitting $4.1684. The company’s stock had a trading volume of 50,767 shares. The company’s market cap is $125.66 million. The stock has a 50-day moving average of $4.69 and a 200-day moving average of $4.88. Trovagene has a 12-month low of $2.85 and a 12-month high of $7.18.
Trovagene (NASDAQ:TROV) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by $0.03. Trovagene had a negative net margin of 8,495.00% and a negative return on equity of 80.13%. On average, equities research analysts forecast that Trovagene will post ($1.34) EPS for the current year.
Trovagene Company Profile
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Receive News & Ratings for Trovagene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trovagene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.